Cargando…
A Review on Iron Chelators in Treatment of Iron Overload Syndromes
Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using mor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139945/ https://www.ncbi.nlm.nih.gov/pubmed/27928480 |
_version_ | 1782472336168976384 |
---|---|
author | Mobarra, Naser Shanaki, Mehrnoosh Ehteram, Hassan Nasiri, Hajar Sahmani, Mehdi Saeidi, Mohsen Goudarzi, Mehdi Pourkarim, Hoda Azad, Mehdi |
author_facet | Mobarra, Naser Shanaki, Mehrnoosh Ehteram, Hassan Nasiri, Hajar Sahmani, Mehdi Saeidi, Mohsen Goudarzi, Mehdi Pourkarim, Hoda Azad, Mehdi |
author_sort | Mobarra, Naser |
collection | PubMed |
description | Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications. |
format | Online Article Text |
id | pubmed-5139945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-51399452016-12-07 A Review on Iron Chelators in Treatment of Iron Overload Syndromes Mobarra, Naser Shanaki, Mehrnoosh Ehteram, Hassan Nasiri, Hajar Sahmani, Mehdi Saeidi, Mohsen Goudarzi, Mehdi Pourkarim, Hoda Azad, Mehdi Int J Hematol Oncol Stem Cell Res Review Article Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2016-10-01 /pmc/articles/PMC5139945/ /pubmed/27928480 Text en Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Mobarra, Naser Shanaki, Mehrnoosh Ehteram, Hassan Nasiri, Hajar Sahmani, Mehdi Saeidi, Mohsen Goudarzi, Mehdi Pourkarim, Hoda Azad, Mehdi A Review on Iron Chelators in Treatment of Iron Overload Syndromes |
title | A Review on Iron Chelators in Treatment of Iron Overload Syndromes |
title_full | A Review on Iron Chelators in Treatment of Iron Overload Syndromes |
title_fullStr | A Review on Iron Chelators in Treatment of Iron Overload Syndromes |
title_full_unstemmed | A Review on Iron Chelators in Treatment of Iron Overload Syndromes |
title_short | A Review on Iron Chelators in Treatment of Iron Overload Syndromes |
title_sort | review on iron chelators in treatment of iron overload syndromes |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139945/ https://www.ncbi.nlm.nih.gov/pubmed/27928480 |
work_keys_str_mv | AT mobarranaser areviewonironchelatorsintreatmentofironoverloadsyndromes AT shanakimehrnoosh areviewonironchelatorsintreatmentofironoverloadsyndromes AT ehteramhassan areviewonironchelatorsintreatmentofironoverloadsyndromes AT nasirihajar areviewonironchelatorsintreatmentofironoverloadsyndromes AT sahmanimehdi areviewonironchelatorsintreatmentofironoverloadsyndromes AT saeidimohsen areviewonironchelatorsintreatmentofironoverloadsyndromes AT goudarzimehdi areviewonironchelatorsintreatmentofironoverloadsyndromes AT pourkarimhoda areviewonironchelatorsintreatmentofironoverloadsyndromes AT azadmehdi areviewonironchelatorsintreatmentofironoverloadsyndromes AT mobarranaser reviewonironchelatorsintreatmentofironoverloadsyndromes AT shanakimehrnoosh reviewonironchelatorsintreatmentofironoverloadsyndromes AT ehteramhassan reviewonironchelatorsintreatmentofironoverloadsyndromes AT nasirihajar reviewonironchelatorsintreatmentofironoverloadsyndromes AT sahmanimehdi reviewonironchelatorsintreatmentofironoverloadsyndromes AT saeidimohsen reviewonironchelatorsintreatmentofironoverloadsyndromes AT goudarzimehdi reviewonironchelatorsintreatmentofironoverloadsyndromes AT pourkarimhoda reviewonironchelatorsintreatmentofironoverloadsyndromes AT azadmehdi reviewonironchelatorsintreatmentofironoverloadsyndromes |